Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600–mutant tumours

AIMS: The effect of repeat oral supratherapeutic dosing of the BRAF inhibitor dabrafenib on QTc interval was assessed in patients with BRAF V600–mutant tumours. METHODS: Part 1 of this phase 1, multicentre, 2‐part study (BRF113773/NCT01738451) assessed safety/tolerability of dabrafenib 225 or 300 mg...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Br J Clin Pharmacol
Prif Awduron: Nebot, Noelia, Arkenau, Hendrik‐Tobias, Infante, Jeffrey R., Chandler, Jason C., Weickhardt, Andrew, Lickliter, Jason D., Sarantopoulos, John, Gordon, Michael S., Mak, Gabriel, St‐Pierre, Annie, Tang, Lihua, Mookerjee, Bijoyesh, Carson, Stanley W., Hayes, Siobhan, Grossmann, Kenneth F.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2018
Pynciau:
Drug Safety
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5867134/
https://ncbi.nlm.nih.gov/pubmed/29243287
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13488
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg